Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

In 2020, Sue volunteered for a study at the Washington University School of Medicine in St. Louis. Researchers there were conducting part of a nationwide clinical trial of Leqembi, then known by its ...

Diagnosing Alzheimer's disease before people have any symptoms is possible, but brings up concerns when so few treatments are ...

In 2020, Sue volunteered for a study at the Washington University School of Medicine in St. Louis. Researchers there were ...

In October 2024, the TGA made the decision not to register lecanemab (LEQEMBI) on the Australian Register of Therapeutic Goods (ARTG) for the ...

Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Her husband ...

Researchers at Washington University School of Medicine in St. Louis analyzed ... after taking two specific treatments: lecanemab (Leqembi) and donanemab (Kisunla). Both FDA-approved medications ...

In 2020, Sue volunteered for a study at the Washington University School of Medicine in St. Louis. Researchers there were conducting part of a nationwide clinical trial of Leqembi, then known by ...